<SEC-DOCUMENT>0001144204-14-035833.txt : 20140624
<SEC-HEADER>0001144204-14-035833.hdr.sgml : 20140624
<ACCEPTANCE-DATETIME>20140605105743
ACCESSION NUMBER:		0001144204-14-035833
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140605
FILED AS OF DATE:		20140605
DATE AS OF CHANGE:		20140605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dehaier Medical Systems Ltd
		CENTRAL INDEX KEY:			0001474627
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34661
		FILM NUMBER:		14892765

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
		BUSINESS PHONE:		(8610) 5166-0080

	MAIL ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v380757_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>U.S. SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of June 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-34661</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dehaier Medical Systems Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dehaier Medical Systems Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Room 501, 83 Fuxing Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Haidian District, Beijing 100856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">People&rsquo;s Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">Form 20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Cautionary
Note Regarding Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Report, including
the exhibits included herein, may contain forward-looking statements.&nbsp;&nbsp;We have based these forward-looking statements
on our current expectations and projections about future events.&nbsp;&nbsp;Our actual results may differ materially from those
discussed herein, or implied by, these forward-looking statements.&nbsp;&nbsp;Forward-looking statements are generally identified
by words such as &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;plan,&rdquo; &ldquo;project&rdquo; and other similar expressions. In addition, any statements that refer to expectations
or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements included
in this Report are subject to significant risks and uncertainties,&nbsp;including but limited to:&nbsp;risks and uncertainties&nbsp;associated
with the integration of the assets and operations we have acquired and may acquire in the future; our possible inability to raise
or generate additional funds that will be necessary to continue and expand our operations; our potential lack of revenue growth
and other factors&nbsp;detailed in the Company&rsquo;s filings with the Securities and Exchange Commission. These forward-looking
statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond
the Company&rsquo;s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as
a result of new information, future events or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 5, 2014, Dehaier Medical Systems Limited issued a press release announcing that it received approval from the China Food and
Drug Administration (CFDA) for its Morpheus Ox software.&nbsp;&nbsp;A copy of the press release is attached as Exhibit&nbsp;99.1
hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%">99.1</TD>
    <TD STYLE="font-size: 10pt; width: 95%">Press Release dated June 5, 2014.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.95pt">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt"><B>DEHAIER MEDICAL SYSTEMS LIMITED</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 42%; padding-right: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">June 5, 2014</TD>
    <TD STYLE="padding-right: 5.4pt">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 5.4pt; text-align: center">/s/ Ping Chen</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: center"><B>Ping Chen</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: center"><B>Chief Executive Officer</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: center"><B>(Principal Executive Officer) and</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: center"><B>Duly Authorized Officer</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">99.1</TD>
    <TD STYLE="width: 95%">Press Release dated June 5, 2014.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v380757_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 60.2pt; width: 169.35pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dehaier Receives CFDA Approval for Morpheus
OX Sleep Diagnostic Software</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BEIJING, June 5, 2014 - Dehaier
Medical Systems Ltd. (NASDAQ: DHRM)</B> (&ldquo;Dehaier&rdquo; or the &ldquo;Company&rdquo;), an emerging leader in
development, assembly, marketing and sale of medical devices and sleep respiratory products in China, today announced that it
had received approval from the China Food and Drug Administration (CFDA) for its Morpheus Ox software.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dehaier Medical applied to the CFDA
to register the Morpheus Ox software in July 2013. With completion of this registration, we have collected all certifications
for four key components of Dehaier&rsquo;s Sleep Respiratory Solutions: the second generation DHR998 Sleep Diagnostic Device,
photoplethysmography (PPG) sensor, sleep diagnostic software and continuous positive airway pressure ventilator in order to
establish a comprehensive product line for Obstructive Sleep Apnea. Dehaier&rsquo;s Morpheus Ox products assist with the
diagnosis of sleep apnea, provide treatment options to apnea patients and allow post-treatment evaluation services to
pinpoint further opportunities for improvement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dehaier Chairman and CEO Mr. Ping Chen
stated, &ldquo;We are confident that China&rsquo;s sleep respiratory market, which is still at an early stage of development, has
tremendous growth potential and that our products position us well to increase market share. Our comprehensive line of products
focused on disease diagnosis, treatment and curative effect evaluation provide a one-stop solution to meet market demand. After
the receipt of the fourth registration certificate for our Morpheus Ox product line, we are ready to launch the solution for sale.
We showcased the Morpheus Ox System and workstation at the 2014 Third Annual Jiangxi Sleep Medicine Seminar from May 30 to 31,
2014. Based on our marketing campaign during the past couple months, we are excited to see strong interest from a variety of hospitals
and physical examination centers. We are beginning to further our marketing and sales activities for our sleep respiratory products
nationwide, and we expect our sleep respiratory business will grow through the rest of 2014 as we move toward mobile health care
and telemedicine.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About the Morpheus Ox System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Morpheus Ox System is a cost-effective,
portable home sleep diagnostic and monitoring solution. By collecting and recording the physiological data from patients who wear
the watch-sized device at home, the advanced automatic sleep scoring software makes an accurate and reliable sleep diagnosis, including
Apnea Hypopnea Index (AHI), sleep/wake time, and Cheyne-Stokes breathing patterns. The new generation Morpheus Ox is a comprehensive
platform that manages a cost-effective sleep services operation, including patient electronic medical records, cardiac and sleep
diagnostics results, as well as complete workflow management. The web-based automatic scoring and data management are able to increase
operational efficiency and provide opportunities for us to offer other services by giving users valuable and timely clinical information
to improve patient treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; color: #365F91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>About Dehaier
Medical Systems Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Dehaier is an
emerging leader in the development, assembly, marketing and sale of medical products, including medical devices and sleep respiratory
products. The company develops and assembles its self-branded medical devices and sleep respiratory products from third-party components.
The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy),
HEYER (Germany) and Timesco (UK). Dehaier's technology is based on six patents and ten software copyrights. More information may
be found at http://www.dehaier.com.cn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Forward-looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">This news release
contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements
include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and
other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance, fulfillment of bids and contracts, changes in technology, economic
conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company
with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by
or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements
to reflect events or circumstances after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">Dehaier Medical Systems
Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">+86 10-5166-0080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">Surie Liu lius@dehaier.com.cn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">Janice Wang wangxq@dehaier.com.cn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!0`.(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`**KSW"PCNSG.U1U)QD#ZG!Q3X9DGA26-MR,`RD=P:+:"NMB6BBB@84444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!12"HI
MIO)4,(V?/92`?U(H!DM5+V8P6S2]%'WFZ[1TW8]!U/MFL+5_$]Q9`K%#:QN>
MAN;D$GZ)&&8_ABN7O_$^OL/FNGCB8'(CTK8O_?4[C/Y5M3H2D93JQB;VH:B4
MRSEE;)W!>64K\S!1W93\X'\2D@5!I7B86FH;+@H+.:15D*-E897Y1U/>*7J#
MV;(/7CA[;6?/=K.XFD>6)`5=98S++$O(8",D"6(Y93_$H*G-->Y"LT<D<<RA
M64QQ<+,C#<Z+Z*ZXEC_NL&`]*ZOJ[UC8YO;:W1[G17"^%_%HETYM/GG6XO[8
M`1RN<">`C*S$]AM^\>Q!'4UTEIJ8;:LI.3C!Q@\\C([$]0HR0.3BN*5.479G
M7&HI*YKT9IH97&5((]0<UYYJOQ.6U\?1>%;#3TN9"RI).\XC56(R0,CG`]^3
MQ4%K4]%HKRW7_C`NB6BROH,XDD;:@>ZB(..3G8S$<>V*LZ5\56OM.@N9O#]R
MK2C<!%<PD%2>"-S`Y([$"E<=CTFBN)\:>/D\&6]C/+ICW4=UP56=5D0\$94Y
M)')Y'`(QW%5=:^)2V2Z9_8^B7NK/?1B8"-2@C#<`,2"`V<Y'&,>],+,]`HKB
M7\>3VL<1O/#&IV[R$*`TL`!;&<`F09K<.OP6_AQ];U&&6Q@CC:1XYBI90"<?
M=)!)XP`><B@+,VJ*\L\-?%VX\0SS.OA?4FLHN#+:(9R&XP"``!QD]:W+[XE:
M?I=HUW?Z+KUK;J0&EFL2J@DX`R3C.:5PLSMZ*YSPSXPT_P`6Z?/?Z9%="WB<
MH7FCVAB!DA>3G&1^=<OIGQALM9:Y&GZ'J,PMD,DS;XE$:YQDEF``IA9GI=%<
M):_$9KZ$R6GAV]GC4[2T=U;D`^F1)UK8T7Q+<:O>-`^AWMG&%)\Z22)E![`[
M6)!/...U`69T=%<SJWCC0M)BU-I;EII=,56NH(4)=`Q`'7`/)'>L)?BG'?Z;
M]LT7POXAU%6.(REH1&V#@_."1Q@]CSQ0%F>ATE<1!\0Y&MT>X\'^*(IBN71-
M/+!3Z`Y&1[X%=A;S"YMH9@DD?F('V2+M9<C.".Q'0CL:!6+%%%%`!1110`55
MO$#6S;MI`&?F`(_4$?I5JFL`RD'.#P<4+035T<-JB2-$R02/@@DK;^8V?JL2
MK^K`5PFHQV5M(?M#00R=3YKVT3?B#YLGYG-=SX^BMX[6QMRTF)IS)-F1N(8E
M,C\9Q@X`/UKRLZ9&C*[0*'AC,CHJCE@OF,./]N2-1[#%>KA$FKWL<%=M2L17
M5RD\JMILJR7<#"2,P/+(RD'@X$:K_2F7FKC[.K1JT,HY6,`AHSNR4`/(*2?,
MO^RQ%;W@C7;;PIXEU"&2Q>XC*K"TT/,B[!\Q"_Q*6R3CD8%9=_KEAK'BZ]UN
M&!K5F8",$;FC(`&\*>#*<<#H#R3Q78F_:-<NB6YSM+EO?Y&YH:-IT&Z1(_M+
MO^\C8X16!+K`#V1"3+)V&`O7(KK=.U/?U,CDA3SQ(^_[H]I)3EC_`'4`'';B
M+24W&S;'%L"E4A=\Q[5.Y@S?\\E/S2.>78!1P*]!\%Z4URT>KW!=H5+-:F5<
M/,[??N&'8L.%'\*@#O7!B4E=LZ:-W9(Z^R@>"$>:P:0XR%X5?15'8#IZGO7A
M7BDS6/Q\@V2B=Y_+4><H(C#J5(4`<8!.#R03GDU]!5XSXX\`^*]:^)::UHHB
MMX46(1W;RJ-C*.3MY)P?:O,9WQT/.M/MK33-(CM;N/2II$U&.Z:XD:12T:@@
MPG,?0GGKCV-3W=M9:K;_`&:VBTFT,VJ-=+<H9&VQ,`!$,1C*@\YSCV%=*O@C
MQGHM[J&G7]I<^(=(O[?RY&AN0"&R&5UWD[65AW&""?6H_#GA_P`<:1XCL[BX
MT75KG3+0[;:S>_554`G:&(X(!))XY^G%*Q=S;^/4GV?P_H42I&7\YL3;?F7:
MH^Z>H![CO@>E<-XUO+B\\9:(EU%?RJ;*U65';#W0YRRX/(;)`/!)]*]1^+OA
M+6_%EAH\&E6BRR12NTN9558P5`Y)(SR#T%5]<^%&I:UK6CZI%K$5E+8VEO$0
M(BY#Q\E@<@'D\9':FT)-'C&JP6;Z%+>P039^VB)9!$5CC&UB4)+$ENF..@/-
M?0'@Z+3=3^$VF)K-F/L,%J&E6Z7"D(,[QSRO<&N"\8_#SQ%=W`TK38KF\$ER
M)I9VMH((&)4_,64Y)&2""!WQGBN[U7P)JM_X!TWPQ;:XEG%!;K#=,(-PG``P
M!R"!D'ZCK18&T>0WOB;5M;TSQ%;Z`D.F>&+11*;>&(+\I=57)'.YB`3SV(Z"
MLVUU;7=-\'6-U.(=0T.6_;=;W,>]1*H4D$GD94\8/KBO5-8\"3^&?AG<^'-$
ML+C5+O47!GN8]JX8,I!()R%P"`!G!R3UJ_X6^&KI\,9O#>O[%DN9FG_=')A8
MXVD'H2,=N,$BE8=U8ZWPO/I%UX1MKG0H(K?3YHBZ11@`(3G<"!W!R#]*\(^%
M&G1ZI/XAM9=,&IJT$9^R&?RA)B0=6[8ZX/7%>M>`_`NI^"X;RS;6Q>Z?+N:.
MW\C85<X&X')QD#D#C/-<'X#\'>._"UYJDL.CQ(]U!Y2R27:*8SDD%<!@2/0C
M%-B5CDO'0L5\9:?I]OHEEI0LT2.>W%RKH3N+?.X&`<$`YR1WKWSPH67S##X7
ML])LYD$BSVL\3K*>W"`9X)(//ZUP>C>`M8TI-2\_PS:ZC-J*E+B:[U0%BI.2
M`0@P2<'/7('I73>`=$\0>'&;3KBT$6EG+H)+[SS">?E0!!P2<G)XQ[T(&]#B
MOB'IDVDZCXPN1=:?*NJ6L3"`7&VXB"LI)\O!R"0><CUK;^&_AJVU_P"&FC/<
M7FI6YA:<#['=M"&!E8\A3@XQQ]36;XV\+:R=6\0W9L+S4[W5K=(;1[.`>3;Q
MAER&8MD-A1T&.2<\\=QX#TN]\(_#NSM-2MI&N8M[R0VZ^:PW.2``.I`(SC/>
MCJ%]#SKP)!J7BSQM=7-AK.JV>B:9*I,,UZ\LDIR<`Y.,':2>P'`]:]YQ7EGP
M>\+ZQH"ZU<:K9M:+>2(85D(W$`MDD`\=1UYKU2F2V%%%%`!1110`4444`<#X
MUMWO]96#;E!:+!_W_G16_P#'48?C7*+;B28W#C"R2+,>.,%Y;@_^.QQCZ8KT
M?4+=I;V6?:2=Z[>.HC!*_F[X_"LJ71HS`8$48*F,<9R"BP#\QO(]LUVT:W+&
MQRSIMR;/(-*M)SG>ADDDS,T+H2PR<[@H(8CGAXR2.XS6PVG6.J1>;=HK@':)
MVDVLIY&!<*"I/^S*H(Z9KT'4?AS`(B-(D1(P=WV*Z!>'=ZHP.^(^ZG\*PGTN
MZL+D&]MY[:48`FG+$$<\"ZB&2/02J?>NKZU&>VYA["4=T5M'\)QI=P&YFDEL
M&8%[>5`C3!<;$$@)C=`>=JD9/4$UZW;R))"&0$*.,%<$8[$'I7):9:B*-=@V
M^;W`3$GXK\DGT(5O?-==!$(H40#&`.!G`]AGFO/KS<W=LZJ4%%:(GS7FOBSQ
M3KEKXDUFTTZ]CM;72M(-\Y,`D+R9^523T!'IZ5Z5BN<U'P3H.K7]Q>WEF\DU
MPJ)/B9U655^Z&4$`@8Z$5@;HR+KQY)I6A^&Y;RS274=8C4A1(8XT.T%F)P2`
M,CH#UIEWXZN)?AOJ?B.*Q>QNK</'''-\PWA@H/(&021U`KH]2\,Z3JQLFN;;
M$ECG[-)$[1M%D`$*5((&`!CV%)/X7TBYT/\`L::U,EB6#M&TC$LP8-DMG))(
MR<FEJ.Z,GP[XNN;^]N]*U.R\B]L+2*XFE2561]ZY]`%/?!X]ZJZ1\1(]3\26
M&CK9Q'[9%)*DUO="8(%!)#?*!V(R"1GN:Z1/#VEQW>HW(LT,NHQK'=%B2)%5
M2H!!.`,''&*IZ7X*T'1;^&]L+(I/!$8HF:9V\M"<E5!)`'7@#O1J!C6WCCR;
M3Q9JETLLMEH]T8(T55!8KP0",=21R>E6O#'C=_$.HRVDVEO:*MJMR)A(73!Q
ME22JX89YQD>]:D7A31(]*O\`3%L5-G?RM-<QL['S'8C)))SU`[]JFL/#NG:=
M%+'!'+B6,1,99WD.P9`4%B2`,G@8HU#0P_"7C+4/%8BNH_#[V^F.9!]K>Z4Y
M*G``7`)R<\\8QWKK+NX6TLI[AONQ1M(<^@!/]*K:/I-CH>FPZ;IT`@M(01&@
M8G&22>22>I)JQ>6D-]93VEPI>*:-HY%R1E6&",CD<$]*8CQ;3?BMXB_X1_4?
MM\,1U>6%;C3L1`*8B&+N<<$*%)Y[X%=7;_$*>Q\->&9-1MUN=4UA&?`;RD4#
MDL2`2!@C@`YYKK_^$;TD:%_8GV118"`VX0,0?+(P5W9SW/>J]SX0T6Z33U:U
M=&TY?+M'AF:-XEQ@@,I!P0,<FE9CNC$3XA^;HVDW*Z-.M]J=X;."TDD"X8'E
MBQ&0H'.<9YZ5CQ^/=5'@_P`2ZS=!4>UU$V=FD*JQ7YE7J1AN2>2.U=I<^$-$
MN[*TM)K,F.SD\RW<2L'1B<E@X.[)/4YYJ,>"?#ZZ(-'%@?L/VC[3Y7FL<R9S
MDG.3SV)Q1J%T5]1\4W-EJVG:):::U_J5S:&Z<-,(555X))P>2<@#`'N*9XB\
M9C0%B5[:W\YK5KEHIKP(P`ZJ`H8D]><!>.M:6J>%='UJ^AO+ZUWW$49B$B2,
MA*$Y*G:1E2<\'(Y-1ZKX-T/6KI;F]LB9A`;;?'*T9,1_@.TC(Y/!HU#0P)O&
MMW?'P:^GP^0-;F+2QRC<RQ*I)`(_//I7?US=QX)T*[CTU'M9(_[-C,5H89W0
MQ*0`0"I!YP/>MRWB2WMXX4+;8U"C<Q8X`QR3R?J>M`F6****8!1110`4444`
M(0#U%,\J,$'8,C&#CTSC^9_.I**+@%)@$8-+10!333X(Y3)&GED\LJ@!6],C
MH2/7K[U<HHHN^HD%%%%`PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
-**`"BBB@`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
